AZD1222, a COVID-19 vaccine that has just undergone phase 3 trials, was co-developed by the spin-out company, Vaccitech, based at the University of Oxford and AstraZeneca.
In this new post, the agency discusses the results of the Phase 3 trials.
COVID-19 Oxford vaccine trial results: New summary article
30 November 2020
A new blog post from Onya discusses the results of the recent Covid-19 UK vaccine trial results - a joint collaboration between University of Oxford spinout - Vaccitech and Astrazeneca. Onya continues to provide marketing support relating specifically to COVID-19.